Financial performance 2008/2007
Download Excel table (see terms of use page)
OUR FINANCIAL PERFORMANCE| 2008 | 2007 | 2006 | 2008 compared to 2007 | 2007 compared to 2006 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth % |
Reported growth % |
CER growth % |
Reported growth % |
| Seloken/Toprol-XL | 807 | (667) | 36 | 1,438 | (393) | 36 | 1,795 | (46) | (44) | (22) | (20) |
| Crestor | 3,597 | 714 | 87 | 2,796 | 673 | 95 | 2,028 | 26 | 29 | 33 | 38 |
| Atacand | 1,471 | 123 | 61 | 1,287 | 99 | 78 | 1,110 | 10 | 14 | 9 | 16 |
| Plendil | 268 | (18) | 15 | 271 | (20) | 16 | 275 | (7) | (1) | (7) | (1) |
| Tenormin | 313 | (17) | 22 | 308 | (24) | 12 | 320 | (6) | 2 | (8) | (4) |
| Zestril | 236 | (72) | 13 | 295 | (30) | 18 | 307 | (24) | (20) | (10) | (4) |
| Other | 271 | (34) | 14 | 291 | (14) | 22 | 283 | (12) | (7) | (5) | 2 |
| Total | 6,963 | 29 | 248 | 6,686 | 291 | 277 | 6,118 | – | 4 | 5 | 9 |
PERFORMANCE 2008
Reported performance
CV sales were up 4% as reported to $6,963 million (2007: $6,686 million). Strong growth from Crestor, fuelled by the promotion of the atherosclerosis indication and increased sales of Atacand offset the continuing significant declines in Seloken/Toprol-XL.
Performance – CER growth rates
CV sales were unchanged from 2007 at CER. Crestor sales increased by 26% to $3,597 million. US sales for Crestor for the full year increased by 18% to $1,678 million. Crestor total prescription share in the US statin market increased to 9.9% in December 2008 from 8.6% in December 2007, and was the only branded statin to gain market share. Crestor sales in the Rest of World were up 34% for the full year to $1,919 million, over half of global sales for the product. Sales were up 16% in Western Europe to $836 million and 93% in Japan driving sales growth in the Established Markets and the Rest of World up 33% in total. Sales in Emerging Markets increased by 41%.
Toprol-XL and authorised generic sales of the drug in the US were down 70% for the full year to $295 million. For the full year, Seloken sales in the Rest of World were up 1% to $512 million.
US sales for Atacand for the full year increased 1% to $262 million. Sales in other markets were up 12% to $1,209 million, on a 10% increase in Established Markets and an 18% increase in Emerging Markets.
PERFORMANCE 2007
Reported performance
CV sales rose by 9% from $6,118 million in 2006 to $6,686 million in 2007. Continued strong growth from Crestor more than offset the significant declines in Seloken/Toprol-XL.
Performance – CER growth rates
CV sales grew by 5% at CER. Crestor sales increased by 33% to $2,796 million. In the US, Crestor sales for the full year were $1,424 million, a 24% increase over 2006. Total prescriptions in the US statin market increased 8% for the year; Crestor prescriptions were up 22%. Sales outside the US for the full year increased 45% to $1,372 million, nearly half the total worldwide sales for the product. Sales were up 26% in Western Europe with good growth in France and Italy. Sales in Canada increased 43%.
Global sales of Seloken/Toprol-XL fell by 22% to $1,438 million. US sales of the Toprol-XL product range, which includes sales of the authorised generic were down 30% for the full year, as the full range of dosage strengths were subject to generic competition from August 2007. Sales of Seloken in other markets were up 5% for the full year as a result of growth in Emerging Markets.
Atacand sales in the US were unchanged for the full year whilst sales in other markets increased 12%.
Continued small declines were seen in Zestril (down 10% to $295 million) and Plendil (down 7% to $271 million), with general global falls compensated by increases in discrete markets.
